Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
Isidori A, Loscocco F, Visani G, Paolasini S, Scalzulli P, Musto P, Perrone T, Guarini A, Pastore D, Mazza P, Tonialini L, Pavone V, De Santis G, Tarantini G.
Isidori A, et al. Among authors: musto p.
Br J Haematol. 2022 Nov;199(3):339-343. doi: 10.1111/bjh.18426. Epub 2022 Aug 24.
Br J Haematol. 2022.
PMID: 36002151
Clinical Trial.